Literature DB >> 22918879

Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer.

C F Xu, Z Xue, N Bing, K S King, L A McCann, P L de Souza, V L Goodman, C F Spraggs, V E Mooser, L N Pandite.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22918879     DOI： 10.1093/annonc/mds249

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  10 in total

Review 1.  Pazopanib: a Review in Advanced Renal Cell Carcinoma.

Authors:  James E Frampton
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

Review 2.  Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors.

Authors:  Dominique A Garrison; Zahra Talebi; Eric D Eisenmann; Alex Sparreboom; Sharyn D Baker
Journal:  Pharmaceutics       Date:  2020-09-09       Impact factor: 6.321

Review 3.  Hydrogen Sulfide Biology and Its Role in Cancer.

Authors:  Saadullah Khattak; Mohd Ahmar Rauf; Nazeer Hussain Khan; Qian-Qian Zhang; Hao-Jie Chen; Pir Muhammad; Mohammad Azam Ansari; Mohammad N Alomary; Muhammad Jahangir; Chun-Yang Zhang; Xin-Ying Ji; Dong-Dong Wu
Journal:  Molecules       Date:  2022-05-25       Impact factor: 4.927

Review 4.  Pazopanib: a review of its use in the management of advanced renal cell carcinoma.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

5.  Prevalence of drug-drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management.

Authors:  Audrey Bellesoeur; Ithar Gataa; Pascaline Boudou-Rouquette; Audrey Thomas-Schoemann; Anne Jouinot; Sarah El Mershati; Anne-Catherine Piketty; Camille Tlemsani; David Balakirouchenane; Anthia Monribot; Michel Vidal; Rui Batista; Sixtine de Percin; Clémentine Villeminey; Jérôme Alexandre; François Goldwasser; Benoit Blanchet
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-24       Impact factor: 3.333

Review 6.  PharmGKB summary: pazopanib pathway, pharmacokinetics.

Authors:  Caroline F Thorn; Manish R Sharma; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2017-08       Impact factor: 2.089

Review 7.  Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.

Authors:  Yi Ling Teo; Han Kiat Ho; Alexandre Chan
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

Review 8.  Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing.

Authors:  Remy B Verheijen; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema; Neeltje Steeghs
Journal:  Clin Pharmacokinet       Date:  2017-09       Impact factor: 6.447

9.  Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma.

Authors:  Melissa A Reimers; Maryann M Shango; Stephanie Daignault-Newton; Rachel Dedinsky; Danielle Karsies; Shawna Kraft; Liam Riddle; Jeremy A Felton; Bo Wen; Christina Gersch; James M Rae; Bruce G Redman; Ajjai S Alva
Journal:  Invest New Drugs       Date:  2018-11-05       Impact factor: 3.850

Review 10.  Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer.

Authors:  Brittany A Davidson; Angeles Alvarez Secord
Journal:  Int J Womens Health       Date:  2014-03-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.